Precision BioSciences Showcases ARCUS Platform at Mitochondrial Medicine 2024
Precision BioSciences Showcases ARCUS Platform at Mitochondrial Medicine 2024
Precision Biosciences在《线粒体医学2024年》展示ARCUS平台
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mitochondrial Disease Foundation's (UMDF) Mitochondrial Medicine 2024 Conference being held in Cleveland, Ohio from June 26-29, 2024.
纳斯达克公司Precision BioSciences, Inc.（DTIL）是一家先进的基因编辑公司，利用其新型专有的ARCUS平台开发体内基因编辑治疗，用于复杂基因编辑，包括基因消除、插入和切除，于2024年6月26日至29日在俄亥俄州克利夫兰市举行的United Mitochondrial Disease Foundation（UMDF）Mitochondrial Medicine 2024大会上进行数据展示。